

CONTENTS

TITLE.....	i
RATIFICATION PAGE	ii
ASSERTION	iii
ACKNOWLEDGEMENT	iv
CONTENTS	vi
LIST OF TABLES.....	ix
LIST OF PICTURE	x
LIST OF APPENDICES	xi
LIST OF ABBREVIATIONS	xii
ABSTRACT	xv
INTISARI.....	xvi
CHAPTER I. INTRODUCTION	
A. Background.....	1
B. Problem Formulation.....	2
C. Research Objective.....	2
D. Research Benefit	3
E. Study Originality	4
CHAPTER II. LITERATURE REVIEW	
A. Literature Review.....	5
1. Type II Diabetic	5
1.1. Definition.....	5

1.2. Pathogenesis	5
1.3. Clinical Manifestation	7
1.4. Management	9
2. Diabetic Nephropathy	9
2.1. Diabetic Nephropathy stages	9
2.2. Management for Diabetic Nephropathy (DN).....	10
3. Diabetes Type II Animal Model	10
4. Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 α)	11
5. PGC-1 α in Diabetic Nephropathy	12
6. Captopril and PGC-1 α in Diabetic Nephropathy	12
7. PGC-1 α in Mitochondrial Biogenesis and Diabetic Nephropathy .	13
8. Centella Asiatica, Diabetic Nephropathy, and Diabetes Mellitus .	14
9. Reverse Transcription Polymerase Chain Reaction	15
B. Theoretical Framework	17
C. Conceptual Framework	19
D. Hypothesis	20
CHAPTER III. METHODS	
A. Research Design.....	21
B. Sample Size.....	21
C. Research Variable	22
D. Time and Place	
1. Time.....	23

2. Place	23
E. Research Instrument	23
F. Research Procedure	24
G. Operational Definition.....	27
H. Statistical Analysis	28
I. Research Limitation.....	29
CHAPTER IV. RESULTS AND DISCUSSION	
A. Results	30
1. PGC-1 α Gene Expression.....	30
B. Discussion.....	36
CHAPTER V. CONCLUSION AND SUGGESTION	
A. Conclusion.....	41
B. Suggestion.....	41
REFERENCE	42
APPENDIX	46